Drug Safety

Motives to report adverse drug reactions to the national agency: A survey study among healthcare professionals and patients in Croatia, the Netherlands, and the UK

Sieta T. de Vries, PhD^{1,2}; Petra Denig, PhD¹; Adriana Andrić, MD^{3,4}; Marina Dimov Di Giusti, MD^{3,4}; Alicia Ptaszynska-Neophytou⁵; Linda Härmark, PhD⁶; Peter G.M. Mol, PhD^{1,2,7}; on behalf of IMI Web-RADR work package 3b consortium and SCOPE Joint Action work package 4.

Corresponding author:

P.G.M. Mol, PhD

E-mail: p.g.m.mol@umcg.nl Phone: +31 (0)50-3617861 Fax +31 (0)50-3617889

¹ University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, The Netherlands

² Web-RADR work package 3B

³ Agency for Medicinal Products and Medical Devices of Croatia (HALMED), Croatia

⁴ SCOPE Joint Action work package 4

⁵ Medicines and Healthcare products Regulatory Agency, London, UK

⁶ Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands

⁷ Dutch Medicines Evaluation Board, Utrecht, the Netherlands

Electronic Supplementary Material Table 1. Characteristics of the included healthcare professionals

	Total
n (%)	296
Median age, years (range) ^a	37 (20-71)
Sex ^b	
Male	93 (32)
Female	201 (68)
Other/prefer not to say	1 (0)
Profession	
Primary care physician	35 (12)
Community/primary care pharmacist	101 (34)
Hospital pharmacist	42 (14)
Nurse practitioner	24 (8)
Secondary care/hospital	79 (27)
physician/medical specialist	
Support staff	15 (5)
Accreditation, years	
<5 years	78 (26)
5 – 20 years	137 (46)
>20 years	81 (27)
Ever reported an ADR to the national pharmacovigila	nce center
Yes	239 (81)
No	44 (15)
Don't know/don't remember	13 (4)
Data are expressed as n (%) unless otherwise specified. ^a adverse drug reaction	` '